Case Report: triple therapy with pembrolizumab, ipilimumab, and lenvatinib in mitotane- and radiation-refractory, cortisol-secreting stage IV adrenocortical carcinoma: a genomically guided approach - Top-Institutions - MDSpire

Case Report: triple therapy with pembrolizumab, ipilimumab, and lenvatinib in mitotane- and radiation-refractory, cortisol-secreting stage IV adrenocortical carcinoma: a genomically guided approach

By
Afif Nakhleh
Ahmad Mahamid
Yaniv Yechiel
Leonard Saiegh
Sagit Zolotov
Salomon M. Stemmer
May 4, 2026
0 min

Frontiers In Immunology

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Oncology
#2

Children’s Oncology Group

Monrovia, CA
Key Differentiators
- Pediatric Oncology
#3

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Oncology
#4

Institut Gustave Roussy

Villejuif, France
Key Differentiators
- Oncology
#5

The University of Texas MD Anderson Cancer Center

Houston, TX
Key Differentiators
- Oncology

Original Source(s)

Frontiers In Immunology

Case Report: triple therapy with pembrolizumab, ipilimumab, and lenvatinib in mitotane- and radiation-refractory, cortisol-secreting stage IV adrenocortical carcinoma: a genomically guided approach

by Afif Nakhleh, Ahmad Mahamid, Yaniv Yechiel, Leonard Saiegh, Sagit Zolotov, Salomon M. Stemmer
May 4, 2026

Related Content

Frontiers In Oncology

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

by Manas Ranjan Sahu, Venu Akkanapally, Partha Sarathi Dasgupta, Sujit Basu
May 28, 2026

Stat News

Biotech exec Jeremy Levin on the industry’s strategic turning point

by Adam Feuerstein, Allison DeAngelis, Elaine Chen
May 28, 2026

Frontiers In Pediatrics

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge